At close: December 13 at 4:00:00 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President, Executive Board Member & Director | 885.6k | -- | 1956 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 677.76k | -- | 1954 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 402.3k | -- | 1974 |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Business Officer | 45.62k | -- | 1987 |
| Mr. Douglas F. Kling | Chief Operating Officer | -- | -- | 1973 |
| Ms. Louise Kooij | Chief Accounting Officer | -- | -- | 1976 |
| Mr. Matthew Philippe | Executive VP &Head of Investor Relations | -- | -- | -- |
| Mr. Bob Rambo | Executive Vice President of Marketing | -- | -- | -- |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | -- | -- | 1967 |
| Dr. Sheng Cui Ph.D. | Chief Manufacturing Officer | -- | -- | -- |
NewAmsterdam Pharma Company N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 62
Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Corporate Governance
NewAmsterdam Pharma Company N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
PTIXW Protagenic Therapeutics, Inc.
0.0140
0.00%
TCBPW TC Biopharm (Holdings) Plc
0.0147
+63.33%
YAG2.F Atossa Therapeutics, Inc.
1.0840
+0.93%
APLMW Apollomics, Inc.
0.0097
-3.00%
REVBW Revelation Biosciences, Inc.
0.0120
-5.51%
NRXBF NUREXONE BIOLOGIC INC
0.5397
0.00%
TNG.PA Transgene SA
0.7280
-5.82%
RCKTW Rocket Pharmaceuticals, Inc.
0.0281
-5.39%
NRXPW NRx Pharmaceuticals, Inc.
0.0617
-22.49%
NRSNW NeuroSense Therapeutics Ltd.
0.2500
-37.50%